Newomics Inc. Places Its 100th Mass Spectrometry Front-end System
Berkeley-based precision medicine solutions provider Newomics Inc. has announced the commercial placement of its 100th mass spectrometry front-end system, which has contributed to successful customer applications in the development of biotherapeutics such as Covid-19 antibodies and gene therapy, blood-based clinical diagnosis, and proteomics research.
- Berkeley-based precision medicine solutions provider Newomics Inc. has announced the commercial placement of its 100th mass spectrometry front-end system, which has contributed to successful customer applications in the development of biotherapeutics such as Covid-19 antibodies and gene therapy, blood-based clinical diagnosis, and proteomics research.
- The system is made up of an ion source integrated with breakthrough silicon microfluidic chips including M3 emitters and MEA chips.
- System models include the MnESI system with M3 emitters launched in November 2020, and the DuoESI system with M3 emitters and MEA chips launched in June 2022.
- We will continue to fulfill customer needs and address the challenges in their mass spectrometry workflows in 2023 and beyond.”